EXTON, Pa., Feb. 28 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (NASDAQ:VPHM) today announced it will present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference at 1:30 P.M. ET on Wednesday, March 5, 2008. The conference is being held at The W Hotel, in New York City.
ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com/ and available for a period of 14 days following the conference.
About ViroPharma Incorporated ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com/. DATASOURCE: ViroPharma Incorporated CONTACT: William C. Roberts, Vice President, Corporate Communications, +1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications, +1-610-321-6290, both of ViroPharma Incorporated Web site: http://www.viropharma.com/
|